Degron Therapeutics Raises $40M for Protein Degrader Pipeline

Degron Therapeutics has successfully closed a significant $40 million Series A Extension, injecting crucial capital to propel its innovative molecular glue degrader pipeline through clinical development. This latest funding round, which brings the company's total raised capital to $95 million, was spearheaded by LAPAM CAPITAL and saw robust participation from a distinguished syndicate including GTJA Investment Group, Fortune Capital, CSPC & Growth, ApicHope, GF Xinde, CASSTAR, Kinghall Ventures, and GAGE Capital.

The substantial investment underscores growing investor conviction in the potential of targeted protein degradation (TPD) as a transformative therapeutic modality. This financing will primarily fuel the advancement of Degron's lead program, DEG6498, a first-in-class HuR molecular glue degrader. This novel agent is designed to tackle previously undruggable RNA-binding proteins implicated in a range of challenging diseases, including cancer, inflammatory conditions, and metabolic disorders. The market for TPD therapies is experiencing rapid expansion, driven by its potential to address targets beyond the reach of traditional small molecules.

Beyond the flagship HuR program, the newly acquired funds are earmarked for advancing two distinct immunology-focused programs towards Investigational New Drug (IND) submission, anticipated in 2026. Furthermore, the capital infusion will bolster the ongoing expansion of Degron's proprietary GlueXplorer® molecular glue discovery platform. This sophisticated platform has already demonstrated its power, generating over 10,000 structurally diverse molecular glue degrader compounds built upon more than 150 unique non-IMiD cores, highlighting the breadth of Degron's discovery engine.

Degron Therapeutics, founded in 2021, is at the forefront of developing therapies that harness the power of molecular glues to selectively degrade disease-causing proteins. The company's strategic focus spans critical therapeutic areas such as oncology, inflammation, metabolic diseases, and rare genetic disorders. Their approach is particularly noteworthy for its ability to target proteins that have historically eluded conventional drug discovery methods, opening new avenues for treatment. The company also engages in strategic collaborations, including a notable partnership with Takeda.

The clinical progress of DEG6498, which entered human trials in late 2025 with the first patient dosed in November, is a key driver for this funding. The program is currently in the dose escalation phase of a Phase 1 study for patients with advanced solid tumors. This milestone demonstrates the company's ability to translate its platform innovation into tangible clinical progress. The therapy's mechanism of action, targeting the Human antigen R (HuR) protein, represents a significant scientific advancement in the field of RNA-binding protein modulation.

Lily Zou, Co-founder and CEO of Degron Therapeutics, expressed enthusiasm for the investor support, stating that the financing validates the company's platform and clinical strategy. She emphasized that the capital will accelerate both clinical-stage and preclinical efforts while reinforcing their discovery technology. Similarly, Zhihua Yu, Chairman of LAPAM Capital, highlighted targeted protein degradation as a critical investment area, praising Degron's platform for its prowess in identifying novel targets and compounds for historically intractable proteins. This sentiment is echoed by the collective confidence shown by the diverse group of participating investors.